Retatrutide is an investigational drug — not approved by the FDA or any regulator as of October 2026 — so there is no approved dosing schedule. What exists are clinical-trial protocols: the exact titration regimens Eli Lilly used in its Phase 2 and Phase 3 (TRIUMPH) trials, disclosed in peer-reviewed papers and the company’s official announcements. This retatrutide dosing schedule guide reports those protocols, trial by trial. Nothing here is a dosing recommendation.
The Short Answer
- Phase 3 (TRIUMPH) rule: start at 2 mg once weekly, escalate one step every 4 weeks — 2 → 4 → 6 → 9 → 12 mg — stopping at the assigned maintenance dose (4, 9, or 12 mg).
- Phase 2 used a different system: maintenance doses of 1 / 4 / 8 / 12 mg — the 8 mg step was replaced by 9 mg in Phase 3. Do not mix the two tables.
- Administration in all trials: once-weekly subcutaneous injection. No oral form has been studied.
- Many vendor “dosing charts” online are wrong: schedules starting at 0.25 mg or 0.5 mg conflict with Lilly’s own official releases. Details below.
Retatrutide Trial Dosing at a Glance
| Trial program | Maintenance doses tested | Starting dose | Escalation interval |
|---|---|---|---|
| Phase 2 (NEJM 2023, 48 weeks) | 1 / 4 / 8 / 12 mg | 1, 2, or 4 mg (by group) | Every 4 weeks, up to 12 weeks of titration |
| TRIUMPH Phase 3 (68–80 weeks) | 4 / 9 / 12 mg | 2 mg (all groups) | Every 4 weeks (2→4→6→9→12 mg) |
The Official Phase 3 Titration Schedule
This is the retatrutide dose schedule from Lilly’s official TRIUMPH announcements (multiple 2026 releases, consistent wording — the most authoritative source available):
| Treatment week | 4 mg group | 9 mg group | 12 mg group |
|---|---|---|---|
| Weeks 1–4 | 2 mg | 2 mg | 2 mg |
| Weeks 5–8 | 4 mg (maintenance) | 4 mg | 4 mg |
| Weeks 9–12 | 4 mg | 6 mg | 6 mg |
| Weeks 13–16 | 4 mg | 9 mg (maintenance) | 9 mg |
| Week 17+ | 4 mg | 9 mg | 12 mg (maintenance) |
In plain terms: the 4 mg group reached its maintenance dose at week 5, the 9 mg group at week 13, and the 12 mg group at week 17. The 16-week escalation plus 64-week maintenance structure comes from the published TRIUMPH design paper (Giblin et al.), with dosing blinded to participants and investigators. Some announcements also describe a 24-week blinded extension allowing escalation to the maximum tolerated dose (9 or 12 mg) after the main period.
How Phase 2 Dosing Differed
The Phase 2 trial (Jastreboff et al., NEJM 2023; 338 adults with obesity, 48 weeks, randomized 2:1:1:1:1:2:2) used a different dose ladder that is worth understanding — because the changes between Phase 2 and Phase 3 reveal how Lilly refined the regimen:
- Groups: 1 mg (no titration — stayed at 1 mg all 48 weeks); 4 mg (starting 2 mg); 4 mg (starting 4 mg); 8 mg (starting 2 mg); 8 mg (starting 4 mg); 12 mg (starting 2 mg); placebo.
- Escalation: groups at 4 mg and above titrated every 4 weeks for up to 12 weeks.
- The key change: Phase 3 dropped the 1 mg and 8 mg rungs and introduced 9 mg — with 6 mg added as an intermediate step. This was not arbitrary: it reflected Phase 2 exposure-response modeling, concentrating the tested range where the benefit-tolerability balance looked best.
- Tolerability lesson: the NEJM paper reported that starting at 2 mg produced meaningfully fewer gastrointestinal events than starting at 4 mg — the direct reason Phase 3 standardized on a 2 mg start for everyone.
Why Trials Start Low and Escalate Slowly
The 4-week escalation cadence is a tolerability design, not a formality. Across both phases, gastrointestinal adverse events were dose-dependent, mostly mild-to-moderate, and concentrated in the escalation period — then eased as titration completed. The trial design essentially trades speed for tolerability: reaching 12 mg takes 16 weeks precisely so the GI system adapts stepwise. This is also why the retatrutide starting dose matters more than it looks — the 2 mg vs 4 mg start comparison in Phase 2 is one of the few head-to-head tolerability data points in the entire program.
Dose Reductions: The Rules Most Guides Omit
The TRIUMPH design paper (PMC12673447) includes dose-reduction rules that almost no vendor guide mentions:
- For tolerability: if gastrointestinal events or inadequate oral intake persisted after other mitigation measures — including one attempted step-down-and-re-escalation — permanent dose reduction was permitted.
- For excessive weight loss: if BMI fell to ≤22 kg/m², or the participant felt weight loss was excessive, reduction was allowed.
These rules matter for interpreting the trial: the published results reflect a protocol that actively managed intolerability rather than forcing everyone up the ladder — a nuance lost in every “dosing chart” that shows only the escalation steps.
What Doses Produced What Outcomes
Weight-change results by dose (trial outcomes — not predictions, and cross-trial numbers are not head-to-head comparisons):
| Trial | Population | Key dose results (mean weight change) |
|---|---|---|
| Phase 2 (48 wks) | Obesity, no diabetes | 1 mg −8.7%; 4 mg −17.1%; 8 mg −22.8%; 12 mg −24.2% (placebo −2.1%) |
| TRIUMPH-1 (80 wks) | Obesity/overweight | 4 mg −19.0%; 9 mg −25.9%; 12 mg −28.3% |
| TRIUMPH-2 (80 wks) | Obesity + type 2 diabetes | 12 mg −20.8%; A1C down ~1.5–1.6% |
| TRIUMPH-3 (80 wks) | Severe obesity + CVD | 12 mg −22.6% |
| TRIUMPH-4 (68 wks) | Obesity + knee osteoarthritis | 12 mg −28.7% |
The dose-response is unmistakable within each trial — but compare across trials only with the caveat that populations and durations differ.
Also read: our Retatrutide vs Ozempic comparison for how retatrutide’s triple-agonist mechanism differs from approved GLP-1 drugs, and our Retatrutide Cost: 2026 Buyer’s Guide for pricing and supplier vetting.
Retatrutide Dosing Chart vs Dosage Schedule: Clearing Up the Terms
Search data shows people look for this information under several names — retatrutide dosing chart, retatrutide dosage schedule, retatrutide dose schedule — and they all mean the same thing: the week-by-week escalation plan. There is exactly one authoritative version of it (the Lilly TRIUMPH titration above). If a retatrutide dosing chart you find elsewhere shows different steps, different intervals, or a different starting dose, it is not describing the published trials. The most common error, as noted above, is a 0.25 mg or 0.5 mg start that appears on vendor and clinic sites but in no Lilly disclosure.
A second source of confusion: Phase 2 and Phase 3 numbers get mixed into single “ultimate” charts. Any retatrutide dosage schedule that lists 1 mg or 8 mg as maintenance doses is describing Phase 2 (2023); the current Phase 3 program uses 4, 9, and 12 mg. Citing a blended chart as “the” schedule misrepresents both trials.
What Happens After the Maintenance Dose Is Reached?
Reaching 12 mg at week 17 is not the end of the protocol — it is the beginning of the 64-week maintenance phase, where participants stay at their assigned dose while efficacy and safety are measured. Lilly’s announcements also describe a subsequent 24-week blinded extension in which participants could be escalated to their maximum tolerated dose (9 or 12 mg). In other words, the published retatrutide dosing schedule has three acts — 16 weeks of escalation, 64 weeks of maintenance, and an optional 24-week extension — not just the titration ladder most charts show. Any discussion of “how long” the regimen runs should count all three.
What’s Wrong With Most “Dosing Charts” Online
A warning for anyone comparing sources: several vendor and clinic sites publish retatrutide dosage chart graphics showing titration starting at 0.25 mg or 0.5 mg. These conflict with Lilly’s official releases, which consistently state a 2 mg start across multiple 2026 announcements. There is no published trial supporting a 0.25 mg or 0.5 mg start. When a “chart” disagrees with the trial sponsor’s own protocol disclosures, trust the sponsor.
Approval Timeline: Where Things Stand
- As of October 2026: retatrutide is not approved by the FDA or any regulator; Lilly had not yet submitted a marketing application.
- Next milestone: Lilly announced plans to submit a BLA (biologics license application) in Q1 2027 — announced July 2026, reaffirmed September 2026. If accepted, an FDA decision would be expected late 2027 to 2028.
- Compounding note: the FDA has stated retatrutide cannot be compounded under federal law — a separate legal question from the approval timeline.
Frequently Asked Questions
What is the retatrutide starting dose in clinical trials?
2 mg once weekly in all Phase 3 (TRIUMPH) groups, escalating every 4 weeks. Phase 2 tested both 2 mg and 4 mg starts and found the 2 mg start better tolerated — which is why Phase 3 standardized on 2 mg.
How does the retatrutide dose schedule work?
The Phase 3 schedule escalates 2 → 4 → 6 → 9 → 12 mg at 4-week intervals, stopping at the assigned maintenance dose (4, 9, or 12 mg). The 12 mg group reaches maintenance at week 17. All doses are once-weekly subcutaneous injections in the trials.
Is there a retatrutide dosage chart I can follow?
There is no approved dosing chart because retatrutide is not an approved drug. The tables in this article reproduce clinical-trial protocols — they describe what researchers did, not what anyone should do. Charts starting at 0.25 mg or 0.5 mg found on vendor sites conflict with Lilly’s official trial disclosures.
Can the retatrutide dose be reduced?
In the TRIUMPH trial protocols, yes — permanent dose reduction was permitted for persistent gastrointestinal events (after other measures failed) or if BMI fell to 22 kg/m² or below. This applied within the controlled trial setting.
How long is the retatrutide titration period?
In the TRIUMPH Phase 3 retatrutide dosing schedule, escalation runs 16 weeks (four 4-week steps from 2 mg to 12 mg), followed by 64 weeks at the maintenance dose. The 12 mg group therefore spends its first 17 weeks titrating. Phase 2 allowed up to 12 weeks of titration.
When will retatrutide be approved?
Lilly plans to submit its biologics license application in Q1 2027. An FDA decision would then be expected in late 2027 to 2028, assuming the application is accepted for review.
Researching retatrutide? Trial data is only meaningful against correctly identified material. Browse our retatrutide collection — every batch ships with HPLC and mass spectrometry documentation, plus third-party COA verification.
Advanced research: Retatrutide side effects — what the TRIUMPH trials reported on gastrointestinal events, heart rate, and tolerability by dose.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved by any regulatory authority; all dosing schedules cited are clinical-trial protocols and are not recommendations. Peptides sold on this site are for laboratory research use only and are not intended for human or veterinary use. Consult a qualified healthcare professional for medical decisions.
Leave a Reply